Wisconsin Alumni Research Foundation

Pharmaceuticals & Vitamin D
Pharmaceuticals Vitamin D
Vitamin D Analog “UW-05” for Skin Therapy, Parathyroid and Autoimmune Disease Treatment
WARF: P08422US02

Inventors: Hector DeLuca, Lori Plum, Rafal Barycki, Margaret Clagett-Dame

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a vitamin D analog that may be useful for skin care, hyperparathyroidism and treating autoimmune diseases such as diabetes mellitus and organ rejection.
Overview
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone mobilizes calcium from bones and increases intestinal absorption of dietary calcium. Effective therapeutic concentrations can lead to hypercalcemia; a condition characterized by elevated blood calcium levels, alterations in mental status, muscle weakness and calcification of soft tissues and organs such as the heart and kidneys. Therefore, a need exists for new compounds that provide desirable therapeutic effects without causing dose-limiting hypercalcemia.
The Invention
UW–Madison researchers have developed a vitamin D analog, 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-1α-hydroxyvitamin D3. Known as UW-05, the compound shows high transcription activity, pronounced activity in arresting proliferating cells and inducing their differentiation. Bone calcium mobilization activity is lower compared to the native hormone. UW-05 may be useful against autoimmune diseases, some cancers, skin wrinkles and disorders, inflammatory problems and obesity.
Applications
  • Treatment of some types of autoimmune and inflammatory diseases
  • Anti-cancer agent
  • Skin and psoriasis care
  • Renal osteodystrophy treatment
  • Inhibiting fat-cell differentiation
Key Benefits
  • Excellent intestinal calcium transport activity
  • Mobilization of bone calcium is dose-dependent.
  • Less likely to cause dose-limiting hypercalcemia than calcitriol
  • Can be administered in many forms
Additional Information
For More Information About the Inventors
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847

WARF